MedTrace Logo

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

NCT06191042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-07-03

No results posted yet for this study

Summary

The main objective of this study is to investigate the safety and tolerability of si-544.

Other objectives are to study the metabolism of si-544 in the body and to assess the effects of si-544 on cells of the body's immune system (immune cells) that have been chronically activated by the disease. Likewise, the effect of si-544 on inflammatory responses in the body triggered by the disease and other disease symptoms will be investigated.

Conditions

Interventions

DRUG

si-544

Subcutaneous injection in the abdomen

DRUG

Placebo

Subcutaneous injection in the abdomen

Sponsors & Collaborators

  • FGK Clinical Research GmbH

    collaborator INDUSTRY

  • selectION Therapeutics GmbH

    lead INDUSTRY

Principal Investigators

  • Andreas Klostermann, Dr. · selectION Therapeutics GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-22
Primary Completion
2025-06-23
Completion
2025-06-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06191042 on ClinicalTrials.gov